Ikjae Lee, Grace Jang, Ying Kuen Ken Cheung, Alexander V Sherman, Wendy S Johnston, Frank Diaz, J Americo M Fernandes, Ali A Habib, Nicholas J Maragakis, Sabrina Paganoni, Katherine Burke, Bjorn Oskarsson, Jaimin Shah, Lorne Zinman, Mary Kay Floeter, Senda Ajroud-Driss, Kelly Gwathmey, Terry Heiman-Patterson, Omar Jawdat, Edward J Kasarskis, Yaz Y Kisanuki, James Wymer, Christina Fournier, Ghazala Hayat, Daragh Heitzman, Catherine Lomen-Hoerth, Michael T Pulley, Stephen N Scelsa, David Walk, Stephen A Goutman, Christen Shoesmith, Zachary Simmons, Eric Sorenson, Lauren Elman, Matthew B Harms, Benjamin N Hoover, Rebecca Y Yun, Regina M Santella, Hiroshi Mitsumoto
{"title":"Primary Lateral Sclerosis Natural History Study: Primary Lateral Sclerosis Functional Rating Scale and Other Outcomes Assessment.","authors":"Ikjae Lee, Grace Jang, Ying Kuen Ken Cheung, Alexander V Sherman, Wendy S Johnston, Frank Diaz, J Americo M Fernandes, Ali A Habib, Nicholas J Maragakis, Sabrina Paganoni, Katherine Burke, Bjorn Oskarsson, Jaimin Shah, Lorne Zinman, Mary Kay Floeter, Senda Ajroud-Driss, Kelly Gwathmey, Terry Heiman-Patterson, Omar Jawdat, Edward J Kasarskis, Yaz Y Kisanuki, James Wymer, Christina Fournier, Ghazala Hayat, Daragh Heitzman, Catherine Lomen-Hoerth, Michael T Pulley, Stephen N Scelsa, David Walk, Stephen A Goutman, Christen Shoesmith, Zachary Simmons, Eric Sorenson, Lauren Elman, Matthew B Harms, Benjamin N Hoover, Rebecca Y Yun, Regina M Santella, Hiroshi Mitsumoto","doi":"10.1002/ana.78056","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The primary lateral sclerosis (PLS) consensus diagnostic criteria and functional rating scale (PLSFRS) were recently established to facilitate and optimize future PLS clinical trials. We examined the trajectory of the PLSFRS and other functional outcome measures and biomarkers in the PLS Natural History Study (PLS NHS) to understand their performance in this prospective cohort.</p><p><strong>Methods: </strong>The PLS NHS is a prospective, longitudinal, multicenter study of people living with PLS in different diagnostic categories: early (disease duration <2 years); probable (2-4 years); and definite PLS (4-15 years). PLSFRS scores and other functional outcome measures were collected at baseline, 3-, 6-, 9-, and 12-month follow-up visits. Baseline characteristics were compared between the groups. The slopes of the PLSFRS and other functional outcome measures over 12 months were examined in the overall cohort and subgroups using linear mixed-effect models. The associations between baseline characteristics and the rate of PLSFRS decline were analyzed with linear regression models.</p><p><strong>Results: </strong>A total of 76 participants were included: early (n = 6); probable (n = 26); and definite (n = 44) PLS. Baseline PLSFRS total scores were highest in the early PLS group, followed by the probable and definite PLS groups. In the overall cohort, the PLSFRS total score declined by 0.33 points/month (95% confidence interval [0.27-0.39], adjusted p < 0.05). The rate of decline was steepest in the early PLS group, followed by the probable and definite PLS groups. Baseline neurofilament light chain level was associated with the rate of PLSFRS decline over 1 year (p = 0.001).</p><p><strong>Interpretation: </strong>In PLS, the rate of functional decline, as measured by the PLSFRS total score, is faster during the early phase of the disease. Neurofilament light might serve as a prognostic biomarker in PLS. ANN NEUROL 2025.</p>","PeriodicalId":127,"journal":{"name":"Annals of Neurology","volume":" ","pages":""},"PeriodicalIF":7.7000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ana.78056","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The primary lateral sclerosis (PLS) consensus diagnostic criteria and functional rating scale (PLSFRS) were recently established to facilitate and optimize future PLS clinical trials. We examined the trajectory of the PLSFRS and other functional outcome measures and biomarkers in the PLS Natural History Study (PLS NHS) to understand their performance in this prospective cohort.
Methods: The PLS NHS is a prospective, longitudinal, multicenter study of people living with PLS in different diagnostic categories: early (disease duration <2 years); probable (2-4 years); and definite PLS (4-15 years). PLSFRS scores and other functional outcome measures were collected at baseline, 3-, 6-, 9-, and 12-month follow-up visits. Baseline characteristics were compared between the groups. The slopes of the PLSFRS and other functional outcome measures over 12 months were examined in the overall cohort and subgroups using linear mixed-effect models. The associations between baseline characteristics and the rate of PLSFRS decline were analyzed with linear regression models.
Results: A total of 76 participants were included: early (n = 6); probable (n = 26); and definite (n = 44) PLS. Baseline PLSFRS total scores were highest in the early PLS group, followed by the probable and definite PLS groups. In the overall cohort, the PLSFRS total score declined by 0.33 points/month (95% confidence interval [0.27-0.39], adjusted p < 0.05). The rate of decline was steepest in the early PLS group, followed by the probable and definite PLS groups. Baseline neurofilament light chain level was associated with the rate of PLSFRS decline over 1 year (p = 0.001).
Interpretation: In PLS, the rate of functional decline, as measured by the PLSFRS total score, is faster during the early phase of the disease. Neurofilament light might serve as a prognostic biomarker in PLS. ANN NEUROL 2025.
期刊介绍:
Annals of Neurology publishes original articles with potential for high impact in understanding the pathogenesis, clinical and laboratory features, diagnosis, treatment, outcomes and science underlying diseases of the human nervous system. Articles should ideally be of broad interest to the academic neurological community rather than solely to subspecialists in a particular field. Studies involving experimental model system, including those in cell and organ cultures and animals, of direct translational relevance to the understanding of neurological disease are also encouraged.